



1645  
RECEIVED

JUN 07 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Y. AIDA et al.

Art Unit: 1645

Appl. No. : 09/748,131

Examiner: UNKNOWN

Filed : December 27, 2000

For : A METHOD FOR TYPING POLYMORPHISMS OF BOVINE MHC  
CLASS II GENES

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks  
Washington, DC 20231

Sir:

Further to the disclosure statement filed March 26, 2001, and pursuant to the duty of disclosure set forth in 37 C.F.R. 1.56 and in accordance with the provisions of 37 C.F.R. 1.97 and 1.98, the following commonly assigned, co-pending applications are brought to the attention of the Examiner:

U.S. Application No. 09/557,917, in the name of AIDA, entitled "Methods for Judging the Possibility of the Onset of Bovine Leukemia and Resistance Thereto".

U.S. Application No. 09/763,625, in the name of AIDA, entitled "Antibody for Detecting the Possibility of Onset of Bovine Leukemia".

U.S. Application No. 09/794,366, in the name of AIDA, entitled "Methods for Judging Resistance to the Onset of Bovine Leukemia".

P20428.A04

Applicants note that copies of these applications are attached hereto. The Examiner is invited to review the file wrappers of these U.S. patent applications, including the specifications, claims, disclosure statements, and documents cited therein, at the U.S. Patent and Trademark Office. Of course, if for any reason, the Examiner cannot locate these applications, Applicants will provide any requested materials, if possible.

Further, the following information is brought to the Examiner's attention:

U.S. Patent No. 5,567,809 to APPLE et al.;

U.S. Patent No. 5,582,987 to LEWIN et al.;

U.S. Patent No. 6,090,540 to AIDA, accompanied by family member WO 98/03680;

AIDA et al., "Tumor-associated Antigens on Bovine Leukemia Virus-induced Bovine Lymphosarcoma Identified by Monoclonal Antibodies", Cancer Research, 45, pp. 1174-1180 (1985);

AIDA et al., "Tumor-associated M<sub>r</sub> 34,000 and M<sub>r</sub> 32,000 Membrane Glycoproteins that are Serine Phosphorylated Specifically in Bovine Leukemia Virus-induced Lymphosarcoma Cells", Cancer Research, 52:6463-6470 (1992);

AIDA et al., "Phenotype and Ontogeny of Cells Carrying a Tumor-associated Antigen that is Expressed on Bovine Leukemia Virus-induced Lymphosarcoma", Cancer Research, 53, pp. 429-437 (1993);

AIDA et al., "Cloning of cDNAs and Molecular Evolution of a Bovine MHC Class II *DRA* Gene", Biochem. Biophys. Res. Commun., 204, pp. 195-202 (1994);

P20428.A04

ARMSTRONG et al., "Preferential Site-dependent Cleavage by Restriction Endonuclease PstI", Nucleic Acids Research, Vol. 10, No. 3, pp. 993-1007 (1982);

BROOKER, Genetics Analysis and Principles, p. 79 (1999);

LEVY et al., "Bovine Leukemia Virus Specific Antibodies Among French Cattle. I. Comparison of Complement Fixation and Hematological Tests", Int. J. Cancer, 19, 882-827 (1977);

MIYASAKA et al., "Sheep as an Experimental Model for Immunology: Immunological Techniques in Vitro and in Vivo", Immunological Methods, Vol. III, pp. 403-423 (1985);

STONE et al., "Up-regulation of IL-2 Receptor  $\alpha$  and MHC Class II Expression on Lymphocyte Subpopulations from Bovine Leukemia Virus Infected Lymphocytotic Cows", Veterinary Immunology and Immunopathology, 48, pp. 65-76 (1995);

STONE et al., "Modulation of Bovine Leukemia Virus-associated Spontaneous Lymphocyte Proliferation by Monoclonal Antibodies to Lymphocyte Surface Molecules", Clinical Immunology and Immunovirology, Vol. 83, No. 2, pp. 156-164 (1997); and

"Enzootic Bovine Leukosis", Alberta Agriculture Food and Rural Development, [www.agric.gov.ab.ca/agdex/600/63-07.html](http://www.agric.gov.ab.ca/agdex/600/63-07.html), pp. 1-4 (1996).

Copies of the above-noted documents are enclosed. Each document is listed on the attached PTO-1449 form to permit the Examiner to indicate consideration thereof.

The Examiner is respectfully requested to consider the documents cited above and to confirm such consideration by initialling in the appropriate spaces on the PTO-1449 form and returning a

P20428.A04

copy of the initialled form to Applicants. It is also requested that these documents be identified in the list of references cited on the patent issuing for this application.

The disclosure of the above documents does not constitute an admission that any particular document is relevant or material to the claims, or is prior analogous art with respect to the present application. The citation of these documents is not to be construed as a representation that no better art exists, or that a search has been made.

Applicant notes that an Office Action on the Merits has not issued in the instant application. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Applicant's Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

June 1, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Respectfully Submitted,  
Y. AIDA et al.

*Bruce H. Bernstein*  
*Reg. No. 40,475*  
Bruce H. Bernstein  
Reg. No. 29,027